For patients who do not experience lasting relief from CGRP migraine therapies, it can feel discouraging. However, clinical evidence shows that Botox remains an effective and evidence-based option even after CGRP treatment failure. CGRP therapies target a specific migraine pathway, but chronic migraines often involve multiple
contributing mechanisms. These include peripheral nerve activation, sustained muscle tension, and central pain amplification. Botox addresses these factors through a broader neuromodulatory effect.
Botox works by inhibiting the release of several pain-signaling neurotransmitters at peripheral nerve endings and reducing muscle overactivity in the head and neck. This reduces ongoing nociceptive input to the brain, allowing central pain pathways to recalibrate over time.
Clinical studies and real-world data demonstrate that many patients switching from CGRP therapies to Botox regain preventive benefit. Improvements often include fewer migraine days, reduced headache severity, better sleep, and decreased reliance on acute medications.
Botox also offers practical advantages. It acts locally with minimal systemic exposure, requires treatment only every 12 weeks, and has a strong long-term safety profile. These features make it a reliable option for patients seeking sustainable migraine prevention.
Importantly, migraine treatment is not linear. Failure of one therapy does not mean all options have been exhausted. Botox provides a distinct mechanism of action that remains effective in complex and treatment-resistant migraine cases.
END THE MIGRAINE CYCLE, GET YOUR FREE COPY OF
The Amazing Truth About Migraine Headaches
and What Your Doctor Hasn’t Told You
Send Me The Guide Now
To schedule an appointment, Call Us 905-639-6701 or online at https://www.NabetaDentistry.com/appointment-request